Long-chain polyunsaturated fatty acids regulation of PPARs, signaling: Relationship to tissue development and aging

Prostaglandins Leukotrienes and Essential Fatty Acids

Volumn 114, Issue , 2016, Pages 28-34

  Echeverría, Francisca ^a   Ortiz, Macarena ^a   Valenzuela, Rodrigo ^a   Videla, Luis A ^a  

^a UNIVERSITY OF CHILE   (Chile)

Author keywords

Aging; Long chain polyunsaturated fatty acids; n 3 long chain polyunsaturated fatty acids; Peroxisome proliferator activated receptors; Tissue development

Indexed keywords

FATTY ACID DERIVATIVE; LONG CHAIN FATTY ACID; OMEGA 3 FATTY ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; POLYUNSATURATED FATTY ACID; PROTEIN BINDING; UNSATURATED FATTY ACID;

ADIPOGENESIS; AGING; BINDING AFFINITY; EMBRYO DEVELOPMENT; FATTY ACID METABOLISM; FATTY ACID OXIDATION; FETUS DEVELOPMENT; GENE EXPRESSION REGULATION; HISTOGENESIS; HUMAN; INFLAMMATION; LIPID HOMEOSTASIS; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PLACENTA DEVELOPMENT; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN FUNCTION; PROTEIN LIPID INTERACTION; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION; ANIMAL; CHEMISTRY; FEMALE; LIPID METABOLISM; METABOLISM; PREGNANCY;

ADIPOGENESIS; AGING; ANIMALS; FATTY ACIDS, UNSATURATED; FEMALE; GENE EXPRESSION REGULATION; HUMANS; LIPID METABOLISM; OXIDATIVE STRESS; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS; PLACENTATION; PREGNANCY; PROTEIN BINDING; PROTEIN CONFORMATION; SIGNAL TRANSDUCTION;

EID: 84991687061     PISSN: 09523278     EISSN: 15322823     Source Type: Journal    
DOI: 10.1016/j.plefa.2016.10.001     Document Type: Review

References (105)

1. [1] Viswakarma, N., Jia, Y., Bai, L., et al. Coactivators in PPAR-Regulated Gene Expression. PPAR Res. 2010 (2015), 1–22.
2. [2] Michalik, L., Auwerx, J., Berger, J.P., et al. International union of pharmacology. LXI. Peroxisome proliferator-activated receptors. Pharm. Rev., 58, 2006 (726–4).
3. [3] Semple, R.K., Chatterjee, V.K.K., Rahilly, S.O., PPARγ and human metabolic disease. J. Clin. Investig. 116 (2006), 581–589.
4. [4] Rees, W.D., McNeil, C.J., Maloney, C.A., The roles of PPARs in the fetal origins of metabolic health and disease. PPAR Res 2008 (2008), 1–8.
5. [5] Barak, Y., Kim, S., Genetic manipulations of PPARs: effects on obesity and metabolic disease. PPAR Res. 2007 (2007), 1–32.
6. [6] Gurnell, M., Striking the right balance in targeting PPARgamma in the metabolic syndrome: novel insights from human genetic studies. PPAR Res. 2007 (2007), 1–14.
7. [7] Grygiel-Górniak, B., Peroxisome proliferator-activated receptors and their ligands: nutritional and clinical implications. Nutr. J. 13 (2014), 1–10.
8. [8] Krey, G., Braissant, O., L'Horset, F., et al. Fatty acids, eicosanoids, and hypolipidemic agents identified as ligands of peroxisome proliferator-activated receptors by coactivator-dependent receptor ligand assay. Mol. Endocrinol. 11 (1997), 779–791.
9. [9] Neschen, S., Morino, K., Dong, J., et al. n-3 fatty acids preserve insulin sensitivity in vivo in a peroxisome proliferator – activated receptor- α – dependent manner. Diabetes 56 (2007), 1034–1041.
10. [10] Fruchart, J.C., Staels, B., Duriez, P., The role of fibric acids in atherosclerosis. Curr. Atheroscler. Rep. 3 (2011), 83–92.
11. [11] Raji, A.S., Seely, E., Bekins, S., Williams, G., Simonson, D., Rosiglitazone improves insulin sensitivity and lowers blood pressure in hipertensive patients. Diabetes Care 26 (2003), 172–178.
12. [12] Desvergne, B., Wahli, W., Peroxisome proliferator-activated receptors: nuclear control of metabolism. J. Clin. Endocrinol. Metab. 20 (1999), 649–688.
13. [13] Kersten, S., Desvergne, B., Wahli, W., Roles of PPARs in health and disease. Nature 405 (2000), 421–424.
14. [14] Liu, S., Alexander, R.K., Lee, C.H., Lipid metabolites as metabolic messengers in inter-organ communication. Trends Endocrinol. Metab. 25 (2014), 356–363.
15. [15] Wang, T.Y., Liu, M., Portincasa, P., Wang, D.Q., New insights into the molecular mechanism of intestinal fatty acid absorption. Eur. J. Clin. Investig. 43 (2013), 1203–1223.
16. [16] Mennitti, L.V., Oliveira, J.L., Morais, C.A., et al. Type of fatty acids in maternal diets during pregnancy and/or lactation and metabolic consequences of the offspring. J. Nutr. Biochem. 26 (2015), 99–111.
17. [17] Yashodhara, B.M., Umakanth, S., Pappachan, J.M., Bhat, S.K., Kamath, R., Choo, B.H., Omega-3 fatty acids: a comprehensive review of their role in health and disease. Post. Med. J. 85 (2009), 84–90.
18. [18] Georgiadi, A., Kersten, S., Mechanisms of gene regulation by fatty acids. Adv. Nutr. 3 (2012), 127–134.
19. [19] Moniri, N.H., Free-fatty acid receptor 4 (GPR120): cellular and molecular function and its role in metabolic disorders. Biochem. Pharmcol. 110-111 (2016), 1–15.
20. [20] Lambe, K.G., Tugwood, J.D., A human peroxisome-proliferator-activated receptor-gamma is activated by inducers of adipogenesis, including thiazolidinedione drugs. Eur. J. Biochem. 239 (1996), 1–7.
21. [21] Schild, R.L., Sonnenberg-Hirche, C.M., Schaiff, W.T., Bildirici, I., Nelson, D.M., Sadovsky, Y., The kinase p38 regulates peroxisome proliferator activated receptor-γ in human trophoblasts. Placenta 27 (2006), 191–199.
22. [22] Matsuda, S., Kobayashi, M., Kitagishi, Y., Expression and function of PPARs in placenta. PPAR Res 2013 (2013), 1–7.
23. [23] Iemitsu, M., Miyauchi, T., Maeda, S., et al. Aging-induced decrease in the PPAR-alpha level in hearts is improved by exercise training. Am. J. Physiol. 283 (2002), 1750–1760.
24. [24] Sanguino, E., Roglans, N., Alegret, M., Sánchez, R.M., Vázquez-Carrera, M., Laguna, J.C., Atorvastatin reverses age-related reduction in rat hepatic PPARalpha and HNF-4. Br. J. Pharmcol. 145 (2002), 853–861.
25. [25] Poynter, M.E., Daynes, R.A., Peroxisome proliferator-activated receptor alpha activation modulates cellular redox status, represses nuclear factor-kappaB signaling, and reduces inflammatory cytokine production in aging. J. Biol. Chem. 273 (1998), 32833–32841.
26. [26] Deplanque, D., Gelé, P., Pétrault, O., et al. Peroxisome proliferator-activated receptor-alpha activation as a mechanism of preventive neuroprotection induced by chronic fenofibrate treatment. J. Neurosci. 23 (2003), 6264–6271.
27. [27] Laudet, V., Auwerx, J., Gustafsson, J.A., Wahli, W., A unified nomenclature system for the nuclear receptor superfamily. Cell 97 (1999), 161–163.
28. [28] Lee, M.Y., Lee, Y.J., Kim, Y.H., et al. Role of peroxisome proliferator-activated receptor (PPAR) δ in embryonic stem cell proliferation. Int J. Stem Cells 2 (2009), 28–34.
29. [29] Heras-Sandoval, D., Pedraza-Chaverri, J., Pérez-Rojas, J.M., Role of docosahexaec acid in the modulation of glial cells in Alzheimer's disease. J. Neuroinflamm. 13 (2016), 1–13.
30. [30] Sampath, H., Ntambi, J.M., Polyunsaturated fatty acid regulation of genes of lipid metabolism. Annu. Rev. Nutr. 25 (2005), 317–340.
31. [31] Michalik, L., Desvergne, B., Dreyer, C., Gavillet, M., Laurini, R.N., Wahli, W., PPAR expression and function during vertebrate development. Int J. Dev. Biol. 46 (2002), 105–114.
32. [32] Hashimoto, T., Cook, W.S., Qi, C., Yeldandi, A.V., Reddy, J.K., Rao, M.S., Defect in peroxisome proliferator-activated receptor alpha -inducible fatty acid oxidation determines the severity of hepatic steatosis in response to fasting. J. Biol. Chem. 275 (2000), 28918–28928.
33. [33] Contreras, A.V., Torres, N., Tovar, A.R., PPAR-α as a key nutritional and environmental sensor for metabolic adaptation. Adv. Nutr. 4 (2013), 439–452.
34. [34] Hiukka, A., Maranghi, M., Matikainen, N., Taskinen, M., PPAR α: an emerging therapeutic target in diabetic microvascular damage. Nat. Rev. Endocrinol. 6 (2010), 454–463.
35. [35] Pyper, S.R., Viswakarma, N., Yu, S., Reddy, J.K., PPARα: energy combustion, hypolipidemia, inflammation and cancer. Nucl. Recept Signal 8 (2010), 1–21.
36. [36] Rakhshandehroo, M., Knoch, B., Müller, M., Kersten, S., Peroxisome proliferator-activated receptor alpha target genes. PPAR Res. 2010 (2010), 1–20.
37. [37] Delerive, P., De Bosscher, K., Besnard, S., et al. Peroxisome proliferator-activated receptor α negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NF- κB and AP-1. J. Biol. Chem. 274 (1999), 32048–32054.
38. [38] Ramanan, S., Kooshki, M., Zhao, W., Hsu, F.C., Robbins, M.E., PPARα ligands inhibit radiation-induced microglial inflammatory responses by negatively regulating NF-κB and AP-1 pathways. Free Radic. Biol. Med. 45 (2008), 1695–1704.
39. [39] Wahli, W., Michalik, L., PPARs at the crossroads of lipid signaling and inflammation. Trends Endocrinol. Metab. 23 (2012), 351–363.
40. [40] Zhou, J., Zhang, S., Xue, J., Avery, J., Wu, J., Lind, S.E., et al. Activation of peroxisome proliferator-activated receptor (PPAR) suppresses hypoxia-inducible factor-1 (HIF-1) signaling in cancer cells. J. Biol. Chem. 287 (2012), 35161–35169.
41. [41] Panigrahy, D., Kaipainen, A., Huang, S., et al. PPARalpha agonist fenofibrate suppresses tumor growth through direct and indirect angiogenesis inhibition. Proc. Natl. Acad. Sci. USA 105 (2008), 985–990.
42. [42] Peters, J.M., Lee, S.S., Li, W., et al. Growth, adipose, brain, and skin alterations resulting from targeted disruption of the mouse peroxisome proliferator-activated receptor beta (delta). Mol. Cell Biol. 20 (2000), 5119–5128.
43. [43] Barish, G.D., Narkar, V.A., Evans, R.M., PPAR delta: a dagger in the heart of the metabolic syndrome. J. Clin. Investig. 116 (2007), 590–597.
44. [44] Palomer, X., Barroso, E., Zarei, M., Botteri, G., Vázquez-Carrera, M., PPARβ/δ and lipid metabolism in the heart. Biochim. Biophys. Acta 1860 (2016), 1560–1578.
45. [45] Mandard, S., Zandbergen, F., Nguan, S.T., et al. The direct peroxisome proliferator-activated receptor target fasting-induced adipose factor (FIAF/PGAR/ANGPTL4) is present in blood plasma as a truncated protein that is increased by fenofibrate treatment. J. Biol. Chem. 279 (2004), 34411–34420.
46. [46] Schmuth, M., Haqq, C.M., Cairns, W.J., et al. Peroxisome proliferator-activated receptor (PPAR)-β/δ stimulates differentiation and lipid accumulation in keratinocytes. J. Investig. Dermatol. 122 (2004), 971–983.
47. [47] Rieck, M., Meissner, W., Ries, S., Mu, S., Mu, R., Ligand-mediated regulation of peroxisome proliferator- activated receptor (PPAR) β: a comparative analysis of PPAR-selective agonists and all-trans retinoic acid. Mol. Pharmcol. 74 (2008), 1269–1277.
48. [48] Wang, Y.X., Lee, C.H., Tiep, S., et al. Peroxisome-proliferator-activated receptor δ activates fat metabolism to prevent obesity. Cell 113 (2003), 159–170.
49. [49] Wang, Y.X., Zhang, C.L., Yu, R.T., et al. Regulation of muscle fiber type and running endurance by PPARδ. PLoS Biol. 2 (2004), 1532–1539.
50. [50] Bastie, C., Holst, D., Gaillard, D., Jehl-Pietri, C., Grimaldi, P., Expression of peroxisome proliferator-activated receptor PPARdelta promotes induction of PPARgamma and adipocyte differentiation in 3T3C2 fibroblasts. J. Biol. Chem. 274 (1999), 21920–21925.
51. [51] Tan, N.S., Michalik, L., Noy, N., et al. Critical roles of PPAR β/δ in keratinocyte response to inflammation. Genes Dev. 15 (2001), 3263–3277.
52. [52] Marion-Letellier, R., Savoye, G., Ghosh, S., Fatty acids, eicosanoids and PPAR gamma. Eur. J. Pharmcol. 15 (2015), 1–6.
53. [53] Fajas, L., Fruchart, J.C., Auwerx, J., PPARγ3 mRNA: a distinct PPARγ mRNA subtype transcribed from an independent promoter. FEBS Lett. 438 (1998), 55–60.
54. [54] Rosen, E.D., Spiegelman, B.M., PPARϒ: a nuclear regulator of metabolism, differentiation, and cell growth. J. Biol. Chem. 276 (2001), 7731–7734.
55. [55] Kota, B.P., Huang, T.H.W., Roufogalis, B.D., An overview on biological mechanisms of PPARs. Pharmcol. Res. 51 (2005), 85–94.
56. [56] Berger, J., Moller, D.E., The mechanisms of action of ppars. Annu. Rev. Med. 53 (2002), 409–435.
57. [57] Hoffman, C., Lorenz, K., Braithwaite, S., et al. Altered gene expression for tumor necrosis factor -α and its receptors during drug and dietary modulation of insulin resistance. Endocrinology 134 (2015), 264–270.
58. [58] Miles, P.D.G., Romeo, O.M., Higo, K., Cohen, A., Rafaat, K., Olefsky, J.M., TNF-α-induced insulin resistance in vivo and its prevention by troglitazone. Diabetes 46 (1997), 1678–1683.
59. [59] de Almeida, M., Luquetti, S., Sabarense, C., et al. Butter naturally enriched in cis-9, trans-11 CLA prevents hyperinsulinemia and increases both serum HDL cholesterol and triacylglycerol levels in rats. Lipids Health Dis., 13, 2015, 200.
60. [60] Schoonjans, K., Staels, B., Auwerx, J., Role of the peroxisome proliferator-activated receptor (PPAR) in mediating the effects of fibrates and fatty acids on gene expression. J. Lipid Res. 37 (1996), 907–925.
61. [61] Tontonoz, P., Hu, E., Graves, R.A., Budavari, A.I., Spiegelman, B.M., mPPARϒ2: tissue-specific regulator of an adipocyte enhancer. Genes Dev. 8 (1994), 1224–1234.
62. [62] Salter, A.M., Tarling, E.J., Regulation of gene transcription by fatty acids. Animal 1 (2007), 1314–1320.
63. [63] Simopoulos, A.P., Essential fatty acids in health and chronic disease 1, 2. Am. J. Clin. Nutr. 70 (1999), 560–569.
64. [64] Araya, J., Rodrigo, R., Pettinelli, P., Araya, A.V., Poniachik, J., Videla, L.A., Decreased liver fatty acid delta-6 and delta-5 desaturase activity in obese patients. Obesity 18 (2010), 1460–1463.
65. [65] Pettinelli, P., del Pozo, T., Araya, J., et al. Enhancement in liver SREBP-1c/PPAR-alpha ratio and steatosis in obese patients: correlations with insulin resistance and n-3 long-chain polyunsaturated fatty acid depletion. Biochim. Biophys. Acta 1792 (2009), 1080–1086.
66. [66] Araya, J., Rodrigo, R., Videla, L.A., et al. Increase in long-chain polyunsaturated fatty acid n-6/n-3 ratio in relation to hepatic steatosis in patients with non-alcoholic fatty liver disease. Clin. Sci. 106 (2004), 635–643.
67. [67] Valenzuela, R., Videla, L.A., The importance of the long-chain polyunsaturated fatty acid n-6/n-3 ratio in development of non-alcoholic fatty liver associated with obesity. Food Funct. 2 (2011), 644–648.
68. [68] Videla, L.A., Tapia, G., Rodrigo, R., et al. Liver NF-κB and AP-1 DNA binding in obese patients. Obesity 17 (2009), 973–979.
69. [69] Fernández, V., Tapia, G., Videla, L.A., Recent advances in liver preconditioning: thyroid hormone, n-3 long-chain polyunsaturated fatty acids and iron. World J. Hepatol. 4 (2012), 119–128.
70. [70] Gao, L., Wang, J., Sekhat, K.R., et al. Novel n-3 fatty acid oxidation products activate Nrf2 by destabilizing the association between Keap1 and Cullin. J. Biol. Chem. 282 (2007), 2529–2537.
71. [71] de Roos, B., Mavrommatis, Y., Brouwer, I.A., Long-chain n-3 polyunsaturated fatty acids: new insights into mechanisms relating to inflammatory and coronary heart disease. Br. J. Pharmcol. 158 (2009), 413–428.
72. [72] Tugwood, J.D., Issemann, I., Anderson, R.G., Bundell, K.R., McPheat, W.L., Green, S., The mouse peroxisome proliferator activated receptor recognizes a responseelement in the 5’ flanking sequence of the rat acyl CoA oxidase gene. EMBO J. 11 (1992), 433–439.
73. [73] Pettinelli, P., Videla, L.A., Up-regulation of PPAR-γ mRNA expression in the liver of obese patients: an additional reinforcing lipogenic mechanism to SREBP-1c induction. J. Clin. Endocrinol. Metab. 96 (2011), 1424–1430.
74. [74] Souza-Mello, V., Peroxisome proliferator-activated receptors as targets to treat non-alcoholic fatty liver disease. World J. Hepatol. 7 (2015), 1012–1019.
75. [75] Suruga, K., Mochizuki, K., Kitagawa, M., et al. Transcriptional regulation of cellular retinol-binding protein, type II gene expression in small intestine by dietary fat. Arch. Biochem. Biophys. 362 (1999), 159–166.
76. [76] Nakatani, T., Kim, H., Kaburagi, Y., Yasuda, K., Ezaki, O., A low fish oil inhibits SREBP-1 proteolytic cascade, while a high-fish-oil feeding decreases SREBP-1 mRNA in mice liver: relationship to anti-obesity. J. Lipid Res. 44 (2003), 369–379.
77. [77] Tumova, J., Malisova, L., Andel, M., Trnka, J., Protective effect of unsaturated fatty acids on palmitic acid-induced toxicity in skeletal muscle cells is not mediated by PPARδ activation. Lipids 50 (2015), 955–964.
78. [78] Ruebner, M., Langbein, M., Strissel, P.L., et al. Regulation of the human endogenous retroviral Syncytin-1 and cell-cell fusion by the nuclear hormone receptors PPARgamma/RXRalpha in placentogenesis. J. Cell Biochem. 113 (2012), 2383–2396.
79. [79] Huin, C., Corriveau, L., Bianchi, A., et al. Differential expression of peroxisome proliferator-activated receptors (PPARs) in the developing human fetal digestive tract. J. Histochem. Cytochem. 48 (2002), 603–611.
80. [80] Komar, C.M., Curry, T.E., Localization and expression of messenger RNAs for the peroxisome proliferator-activated receptors in ovarian tissue from naturally cycling and pseudopregnant rats. J. Control Release 66 (2002), 1531–1539.
81. [81] Froment, P., Gizard, F., Defever, D., Staels, B., Dupont, J., Monget, P., Peroxisome proliferator-activated receptors in reproductive tissues: from gametogenesis to parturition. J. Endocrinol. 189 (2006), 199–209.
82. [82] Tarrade, A., Schoonjans, K., Guibourdenche, J., et al. PPARϒ / RXRα heterodimers are involved in human CGβ synthesis and human trophoblast differentiation. Endocrinology 142 (2001), 4504–4514.
83. [83] Meher, A., Sundrani, D., Joshi, S., Maternal nutrition influences angiogenesis in the placenta through peroxisome proliferator activated receptors: a novel hypothesis. Mol. Reprod. Dev. 82 (2015), 726–734.
84. [84] Chen, Z., He, P., Ding, X., Huang, Y., Gu, H., Ni, X., PPARγ stimulates expression of L-type amino acid and taurine transporters in human placentas: the evidence of PPARγ regulating fetal growth. Sci. Rep. 5 (2015), 1–13.
85. [85] Godfrey, K.M., Lillycrop, K.A., Burdge, G.C., Gluckman, P.D., Hanson, M.A., Epigenetic mechanisms and the mismatch concept of the developmental origins of health and disease. Pedia. Res. 61 (2007), 31–36.
86. [86] Lillycrop, K.A., Phillips, E.S., Jackson, A.A., Hanson, M.A., Burdge, G.C., Dietary protein restriction of pregnant rats induces and folic acid supplementation prevents epigenetic modification of hepatic gene expression in the offspring. J. Nutr. 135 (2005), 1382–1386.
87. [87] Tang, C., Cho, H.P., Nakamura, M.T., Clarke, S.D., Regulation of human delta-6 desaturase gene transcription: identification of a functional direct repeat-1 element. J. Lipid Res. 44 (2003), 686–695.
88. [88] Burdge, C., Delange, E., Dubois, L., et al. Effect of reduced maternal protein intake in pregnancy in the rat on the fatty acid composition of brain, liver, plasma, heart and lung phospholipids of the offspring after weaning. Br. J. Nutr. 90 (2003), 345–352.
89. [89] McCarthy, F.P., Drewlo, S., English, F.A., et al. Evidence implicating peroxisome proliferator-activated receptor-ϒ in the pathogenesis of preeclampsia. Hypertension 58 (2011), 882–887.
90. [90] McCarthy, F.P., Drewlo, S., Kingdom, J., Johns, E.J., Walsh, S.K., Kenny, L.C., Peroxisome proliferator-activated receptor-ϒ as a potential therapeutic target in the treatment of preeclampsia. Hypertension 58 (2011), 280–286.
91. [91] Atherton, H.J., Gulston, M.K., Bailey, N.J., et al. Metabolomics of the interaction between PPAR-alpha and age in the PPAR-alpha-null mouse. Mol. Syst. Biol. 5 (2009), 1–10.
92. [92] Yang, L., Zhang, Y., Wang, S., Zhang, W., Shi, R., Decreased liver peroxisomal β-oxidation accompanied by changes inbrain fatty acid composition in aged rats. Neurol. Sci. 35 (2014), 289–293.
93. [93] Sen, C.K., Packer, L., Antioxidant and redox regulation of gene transcription. FASEB J. 10 (1996), 709–720.
94. [94] Zolezzi, J.M., Silva-Alvarez, C., Ordenes, D., et al. Peroxisome proliferator-activated receptor (PPAR) ϒ and PPARα agonists modulate mitochondrial fusion-fission dynamics: relevance to reactive oxygen species (ROS)-related neurodegenerative disorders?. PLoS ONE 8 (2013), 1–10.
95. [95] Pérez-Martín, M., Rivera, P., Blanco, E., et al. Environmental enrichment, age, and PPARα interact to regulate proliferation in neurogenic niches. Front Neurosci. 10 (2016), 1–12.
96. [96] Mozaffarian, D., Marchioli, R., Macchia, A., et al. Fish oil and postoperative atrial fibrillation: the omega-3 fatty acids for prevention of post-operative atrial fibrillation (OPERA) randomized trial. JAMA 308 (2012), 2001–2011.
97. [97] De Caterina, R., n-3 fatty acids in cardiovascular disease. N. Engl. J. Med. 364 (2011), 2439–2450.
98. [98] Mozaffarian, D., Wu, J.H., Omega-3 fatty acids and cardiovascular disease: effects on risk factors, molecular pathways, and clinical events. J. Am. Coll. Cardiol. 58 (2011), 2047–2067.
99. [99] Videla, L.A., Liver NF-κB and AP-1 activation and PPAR-α expression are negatively correlated in obese patients: pro-inflammatory implications. Clin. Nutr. 29 (2010), 687–688.
100. [100] Boyraz, M., Pirgon, Ö., Dündar, B., et al. Long-term treatment with n-3 polyunsaturated fatty acids as a monotherapy in children with nonalcoholic fatty liver disease. J. Clin. Res. Pedia. Endocrinol. 7 (2015), 121–127.
101. [101] Pacifico, L., Bonci, E., Di Martino, M., et al. A double-blind, placebo-controlled randomized trial to evaluate the efficacy of docosahexaenoic acid supplementation on hepatic fat and associated cardiovascular risk factors in overweight children with nonalcoholic fatty liver disease. Nutr. Metab. Cardiovasc. Dis. 25 (2015), 734–741.
102. [102] Scorletti, E., Bhatia, L., McCormick, K.G., et al. Effects of purified eicosapentaenoic and docosahexaenoic acids in nonalcoholic fatty liver disease: results from the Welcome* study. Hepatology 60 (2014), 1211–1221.
103. [103] Linecker, M., Limani, P., Botea, F., et al. A randomized, double-blind study of the effects of omega-3 fatty acids (Omegaven) on outcome after major liver resection. BMC Gastroenterol., 15, 2015, 102.
104. [104] Zúñiga, J., Cancino, M., Medina, F., et al. N-3 PUFA supplementation triggers PPAR-α activation and PPAR-α/NF-κB interaction: anti-inflammatory implications in liver ischemia-reperfusion injury. PLoS One, 6, 2011, e28502.
105. [105] Tapia, G., Valenzuela, R., Espinosa, A., et al. N-3 long-chain PUFA supplementation prevents high fat diet induced mouse liver steatosis and inflammation in relation to PPAR-α upregulation and NF-κB DNA binding abrogation. Mol. Nutr. Food Res. 58 (2014), 1333–1341.